DOCSLIB.ORG

Pharmacotherapy in Dentistry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

V. M. Bobyriov, T. A. Petrova, G. Yu. Ostrovskaya, M. M. Ryabushko, A. A. Kapustianska PHARMACOTHERAPY IN DENTISTRY Vinnytsia Nova Knyha 2020 UDC 616.31(075.8) P 24 Recommended by the Academic Council of the Ukrainian Medical Stomatological Academy as a manual for foreign students-graduands of Master's degree studying "Dentistry" in higher educational institutions of the Ministry of Health of Ukraine (protocol of the meeting of the Academic Council No 11 of 24.06.2020) Reviewers: Igor I. Zamorsky – Doctor of Medical Sciences, Professor, Head of the Department of Pharmacology of the Higher State Educational Institution of Ukraine "Bukovinian State Medical University". Tamara I. Ermolenko – Doctor of Pharmaceutical Sciences, Professor, Head of the Department of Pharmacology and Medical Formulation of Kharkov National Medical University. Authors: Victor M. Bobyriov, Doctor of Medical Science, Professor. Tamara A. Petrova, PhD, Associate Professor of Department of Experimental and Clinical pharmacology with clinical immunology and allergology of Ukrainian Medical Stomatological Academy. Galina Yu. Ostrovska, PhD, Associate Professor of Department of Experimental and Clinical pharmacology with clinical immunology and allergology of Ukrainian Medical Stomatological Academy. Mykola M. Ryabushko, PhD, Associate Professor of Department of Experimental and Clinical pharmacology with clinical immunology and allergology of Ukrainian Medical Stomatological Academy, Dean of Medical Faculty №1. Anna A. Kapustianska, PhD, Associate Professor of Department of Experimental and Clinical pharmacology with clinical immunology and allergology of Ukrainian Medical Stomatological Academy. Pharmacotherapy in dentistry : manual / Bobyiov V. M., P 24 Petrova Т. А., Ostrovska G. Yu., Ryabushko M. M., Kapustianska А. А. – Vinnytsia : Nova Knyha, 2020. – 376 p. : il. ISBN The authors of the book made recommendations to students of dental faculties and practicing dentists on the effective use of pharmacotherapy in dental practice. The book describes the pharmacological characteristics of the main groups of drugs used in den- tistry. UDC 616.31(075.8) © Authors, 2020 ISBN © Nova Knyha, 2020 CONTENTS Foreword ............................................................................................................................... 9 List of conditional abbreviations .............................................................................10 Section 1. Pharmacotherapy in dentistry .........................................................12 1.1. Anesthesia in dentistry ........................................................................................13 1.1.1. Use of general anesthetics ......................................................................16 1.1.2. Use of local anesthetics ............................................................................17 1.1.3. Use of non-narcotic analgesics ..............................................................19 1.1.4. Use of narcotic analgesics .......................................................................21 1.1.5. Pharmacotherapy of pain in therapeutic dentistry ........................22 1.1.6. Pharmacotherapy of pain in neurodentistry ....................................26 1.1.7. Pharmacotherapy of pain in surgical dentistry ................................30 1.1.8. Pharmacotherapy of pain in neoplasms.............................................39 1.1.9. Physical methods of anesthesia ............................................................40 1.2. Pharmacotherapy of diseases of hard tooth tissues ...............................42 1.2.1. Caries ...............................................................................................................42 1.2.2. Non-carious lesions of the teeth ..........................................................55 1.3. Pharmacotherapy of pulpitis .............................................................................57 1.4. Pharmacotherapy of periodontitis .................................................................65 1.5. Pharmacotherapy of periodontal diseases .................................................73 1.6. Pharmacotherapy of diseases of the oral mucosa ...................................88 1.6.1. Xerostomia .....................................................................................................89 1.6.2. Mucosal damage .........................................................................................90 1.6.3. Leukoplakia ....................................................................................................93 1.6.4. Acute herpetic stomatitis .........................................................................94 1.6.5. Chronic recurrent herpetic stomatitis .................................................96 1.6.6. Shingles ...........................................................................................................97 1.6.7. Influenza stomatitis ....................................................................................97 1.6.8. Damage to the mucous membrane in chickenpox ........................98 1.6.9. Damage to the mucous membrane in measles ..............................98 1.6.10. Damage to the mucous membrane in AIDS ..................................98 3 1.6.11. Vincent’s necrotizing ulcerative stomatitis .................................. 100 1.6.12. Vincent’s angina ..................................................................................... 102 1.6.13. Gangrenous stomatitis ........................................................................ 102 1.6.14. Lichen planus........................................................................................... 102 1.6.15. Candidosis ................................................................................................ 105 1.6.16. Actinomycosis ......................................................................................... 108 1.6.17. Allergic lesions ........................................................................................ 109 1.6.18. Chronic recurrent aphthous stomatitis ......................................... 111 1.6.19. Exudative erythema multiforme ...................................................... 112 1.7. Antibacterial therapy of acute inflammatory processes of the maxillofacial area ......................................................................................................... 116 1.7.1. Odontogenic sinusitis ............................................................................. 123 1.7.2. Odontogenic abscess ............................................................................. 123 1.7.3. Periostitis and osteomyelitis ................................................................ 125 1.7.4. Odontogenic phlegmon of the head and neck ............................ 127 1.7.5. Lymphadenitis, adenophlegmon of the head and neck ........... 128 1.7.6. Furuncle, carbuncle ................................................................................. 130 1.8. Local medicinal treatment of wound infections .................................... 132 Section 2. Pharmacotherapy of emergency conditions .......................140 2.1. Acute disorders of blood circulation .......................................................... 142 2.1.1. Faint ............................................................................................................... 142 2.1.2. Collapse ....................................................................................................... 143 2.1.3. Shock ............................................................................................................ 144 2.2. Allergic reactions ................................................................................................. 146 2.2.1. Angioedema ............................................................................................... 146 2.2.2. Anaphylactic shock .................................................................................. 147 2.3. Stenocardia ............................................................................................................ 149 2.4. Hypertensive crisis .............................................................................................. 151 2.5. Acute respiratory failure .................................................................................. 153 2.6. Bronchial asthma ................................................................................................. 155 2.7. Comatose states ................................................................................................... 156 2.8. Convulsive disorders .......................................................................................... 159 2.9. Renal colic ............................................................................................................... 161 2.10. Hepatic colic ........................................................................................................ 162 4 2.11. Injuries to the maxillofacial area ................................................................ 163 2.11.1. Facial contusion ...................................................................................... 163 2.11.2. Facial wounds .......................................................................................... 163 2.11.3. Dental dislocations and fractures .................................................... 164 2.11.4. Mandibular dislocation.......................................................................
Recommended publications
  • Arxiv:1903.01048V1 [Stat.AP] 4 Mar 2019 Author Summary

    Arxiv:1903.01048V1 [Stat.AP] 4 Mar 2019 Author Summary

    Early Detection of Influenza outbreaks in the United States Kai Liu1,3*, Ravi Srinivasan2, Lauren Ancel Meyers1,4 1 Departments of Integrative Biology and Statistics & Data Sciences, The University of Texas at Austin, Austin, TX, US 2 Applied Research Laboratories, The University of Texas at Austin, Austin, TX, US 3 Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX, US 4 Santa Fe Institute, Santa Fe, NM, US * [email protected] Abstract Public health surveillance systems often fail to detect emerging infectious diseases, particularly in resource limited settings. By integrating relevant clinical and internet-source data, we can close critical gaps in coverage and accelerate outbreak detection. Here, we present a multivariate algorithm that uses freely available online data to provide early warning of emerging influenza epidemics in the US. We evaluated 240 candidate predictors and found that the most predictive combination does not include surveillance or electronic health records data, but instead consists of eight Google search and Wikipedia pageview time series reflecting changing levels of interest in influenza-related topics. In cross validation on 2010-2016 data, this algorithm sounds alarms an average of 16.4 weeks prior to influenza activity reaching the Center for Disease Control and Prevention (CDC) threshold for declaring the start of the season. In an out-of-sample test on data from the rapidly-emerging fall wave of the 2009 H1N1 pandemic, it recognized the threat five weeks in advance of this surveillance threshold. Simpler algorithms, including fixed week-of-the-year triggers, lag the optimized alarms by only a few weeks when detecting seasonal influenza, but fail to provide early warning in the 2009 pandemic scenario.
  • Dectova, INN-Zanamivir

    Dectova, INN-Zanamivir

    28 February 2019 EMA/CHMP/851480/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report DECTOVA International non-proprietary name: zanamivir Procedure No. EMEA/H/C/004102/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ......................................................................................... 12 2.1.2. Epidemiology .................................................................................................. 12 2.1.3. Biologic features .............................................................................................
  • Inclusion and Exclusion Criteria for Each Key Question

    Inclusion and Exclusion Criteria for Each Key Question

    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
  • Abuse-Proof Solid Pharmaceutical Composition

    Abuse-Proof Solid Pharmaceutical Composition

    (19) TZZ¥¥ ¥_T (11) EP 3 329 939 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 06.06.2018 Bulletin 2018/23 A61K 47/02 (2006.01) A61K 47/36 (2006.01) A61K 9/16 (2006.01) A61K 31/485 (2006.01) (2006.01) (21) Application number: 17204525.4 A61K 31/192 (22) Date of filing: 29.11.2017 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • BOSCHETTI, Silvia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO I-38060 Aldeno (TN) (IT) PL PT RO RS SE SI SK SM TR • ROSSI, Massimiliano Designated Extension States: I-38121 Trento (IT) BA ME • BENFENATI, Diego Designated Validation States: I-38052 Caldonazzo (TN) (IT) MA MD • POJER, Alessandro I-38092 Altavalle (TN) (IT) (30) Priority: 02.12.2016 IT 201600122469 (74) Representative: Allaix, Roberto (71) Applicant: E-Pharma Trento S.p.A. PGA S.p.A. 38123 Trento (IT) Via Mascheroni, 31 20145 Milano (IT) (54) ABUSE-PROOF SOLID PHARMACEUTICAL COMPOSITION (57) The present invention relates to an abuse-proof solid pharmaceutical composition comprising an active ingre- dient with potential for abuse, silica in an amount of from 10 mg to 1000 mg, guar flour in an amount of from 100 mg to 300 mg, and a water soluble diluent in an amount of from 500 mg to 5000 mg. EP 3 329 939 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 329 939 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to an abuse-proof solid pharmaceutical composition, in particular a solid phar- maceutical composition, such as, for example a granulate or a tablet, capable of solubilizing in a glass of water (about 100 ml), but of forming a not injectable gel and/or viscous solution if added to the amount of water contained in a hypodermic syringe (about 10 ml).
  • Feline Calicivirus Ulcer on Tongue Unilateral Conjunctivitis Typical of Early Chlamydophila Felis Infection Feline Chronic Lymphocytic Plasmacytic Gingivostomatitis

    Feline Calicivirus Ulcer on Tongue Unilateral Conjunctivitis Typical of Early Chlamydophila Felis Infection Feline Chronic Lymphocytic Plasmacytic Gingivostomatitis

    £5.00, $9.00, €7.50 Melchizedek publications www.catvirus.com If you print this book out – please do so on recycled paper! Cover photos – feline calicivirus ulcer on tongue unilateral conjunctivitis typical of early Chlamydophila felis infection feline chronic lymphocytic plasmacytic gingivostomatitis © Diane D. Addie PhD BVMS MRCVS Sep 2006 2 Contents Page Introduction ………………………………………………………………………. 4 Feline calicivirus………………………………………………………………….. 4 Feline chronic gingivostomatitis ………………………………………….. .….. 7 Feline herpesvirus (viral rhinotracheitis)……………………………………….. 10 Chlamydophila felis……………………………………………………………….. 13 Bordetella bronchiseptica ……………………………………………………….. 16 Avian influenza virus H5N1 …………………………………………………….. 17 Poxvirus …………………………………………………………………………… 19 Feline coronavirus ……………………………………………………………….. 19 Haemophilus felis ………………………………………………………………… 19 Aelurostrongylus abstrusus …………………………………………………….. 19 Mycoplasma felis ………………………………………………………………… 20 Corynebacterium spp ……………………………………………………………. 20 Cryptococcus spp ……………………………..…………………………………. 20 Capillaria aerophila ………………………………………………………………. 21 Cuterebra larval migrans ………………………………………………………… 21 Differential diagnoses …………………………………………………………… 22 acute oral ulceration …………………………………… 22 chronic gingivostomatitis……………………………….. 22 chronic rhinitis ………………………………………….. 22 conjunctivitis ……………………………………………. 23 coughing ………………………………………………… 23 fading kittens ……………………………………………. 23 bronchopneumonia of kittens …………………………. 24 Preventing respiratory infection 25 hygiene ………………………………………. 25 barrier nursing
  • Efficacy of Baloxavir Marboxil on Household Transmission Of

    Efficacy of Baloxavir Marboxil on Household Transmission Of

    Umemura et al. Journal of Pharmaceutical Health Care and Sciences (2020) 6:21 https://doi.org/10.1186/s40780-020-00178-4 RESEARCH ARTICLE Open Access Efficacy of baloxavir marboxil on household transmission of influenza infection Takumi Umemura1,2* , Yoshikazu Mutoh2, Takato Kawamura1, Masayuki Saito1, Takahito Mizuno1, Aiko Ota1, Koji Kozaki1, Tetsuya Yamada1, Yoshiaki Ikeda3 and Toshihiko Ichihara2 Abstract Background: Baloxavir marboxil (baloxavir) is a new anti-influenza virus agent that is comparable to oseltamivir phosphate (oseltamivir). Since the efficacy of baloxavir in preventing household transmission of influenza is not well established, we compared the secondary household influenza virus transmission rates between patients on baloxavir vs oseltamivir. Methods: Between October 2018 and March 2019, we enrolled index patients (diagnosed with influenza and treated with baloxavir or oseltamivir) and household members. The secondary attack rate of household members was compared between index patients treated with baloxavir vs oseltamivir. Risk factors of household transmission were determined using multivariate logistic analyses. Results: In total, 169 index patients with influenza type A were enrolled. The median age was 27.0 (interquartile range; 11–57) years. The number of index patients treated with baloxavir and oseltamivir was 49 and 120, respectively. The secondary attack rate was 9.0% (95% confidence interval [CI]: 4.6–15.6) in the baloxavir group and 13.5% (95% CI: 9.8–17.9) in the oseltamivir group. In the multivariate analysis, independent risk factors were 0–6 years of age (odds ratio [OR] 2.78, 95% CI: 1.33–5.82, p < 0.01) and not being on baloxavir treatment.
  • Pdf Files/WHA58- 6

    Pdf Files/WHA58- 6

    Peer-Reviewed Journal Tracking and Analyzing Disease Trends pages 527–680 EDITOR-IN-CHIEF D. Peter Drotman EDITORIAL STAFF EDITORIAL BOARD Founding Editor Dennis Alexander, Addlestone Surrey, United Kingdom Joseph E. McDade, Rome, Georgia, USA Barry J. Beaty, Ft. Collins, Colorado, USA Managing Senior Editor Martin J. Blaser, New York, New York, USA Polyxeni Potter, Atlanta, Georgia, USA David Brandling-Bennet, Washington, D.C., USA Associate Editors Donald S. Burke, Baltimore, Maryland, USA Paul Arguin, Atlanta, Georgia, USA Arturo Casadevall, New York, New York, USA Charles Ben Beard, Ft. Collins, Colorado, USA Kenneth C. Castro, Atlanta, Georgia, USA David Bell, Atlanta, Georgia, USA Thomas Cleary, Houston, Texas, USA Jay C. Butler, Anchorage, Alaska, USA Anne DeGroot, Providence, Rhode Island, USA Charles H. Calisher, Ft. Collins, Colorado, USA Vincent Deubel, Shanghai, China Paul V. Effler, Honolulu, Hawaii, USA Stephanie James, Bethesda, Maryland, USA Ed Eitzen, Washington, D.C., USA Brian W.J. Mahy, Atlanta, Georgia, USA Duane J. Gubler, Honolulu, Hawaii, USA Nina Marano, Atlanta, Georgia, USA Richard L. Guerrant, Charlottesville, Virginia, USA Martin I. Meltzer, Atlanta, Georgia, USA Scott Halstead, Arlington, Virginia, USA David Morens, Bethesda, Maryland, USA David L. Heymann, Geneva, Switzerland J. Glenn Morris, Baltimore, Maryland, USA Daniel B. Jernigan, Atlanta, Georgia, USA Marguerite Pappaioanou, St. Paul, Minnesota, USA Charles King, Cleveland, Ohio, USA Tanja Popovic, Atlanta, Georgia, USA Keith Klugman, Atlanta, Georgia, USA Patricia M. Quinlisk, Des Moines, Iowa, USA Takeshi Kurata, Tokyo, Japan Jocelyn A. Rankin, Atlanta, Georgia, USA S.K. Lam, Kuala Lumpur, Malaysia Didier Raoult, Marseilles, France Bruce R. Levin, Atlanta, Georgia, USA Pierre Rollin, Atlanta, Georgia, USA Myron Levine, Baltimore, Maryland, USA David Walker, Galveston, Texas, USA Stuart Levy, Boston, Massachusetts, USA David Warnock, Atlanta, Georgia, USA John S.
  • View Full Issue

    View Full Issue

    Volume 31, Issue 2, December 2015 ISSN 0204-8809 ACTA MICROBIOLOGICA BULGARICA Bulgarian Society for Microbiology Union of Scientists in Bulgaria Acta Microbiologica Bulgarica The journal publishes editorials, original research works, research reports, reviews, short communications, letters to the editor, historical notes, etc from all areas of microbiology An Official Publication of the Bulgarian Society for Microbiology (Union of Scientists in Bulgaria) Volume 31 / 2 (2015) Editor-in-Chief Angel S. Galabov Press Product Line Sofia Editor-in-Chief Angel S. Galabov Editors Maria Angelova Hristo Najdenski Editorial Board I. Abrashev, Sofia S. Aydemir, Izmir, Turkey L. Boyanova, Sofia E. Carniel, Paris, France M. Da Costa, Coimbra, Portugal E. DeClercq, Leuven, Belgium S. Denev, Stara Zagora D. Fuchs, Innsbruck, Austria S. Groudev, Sofia I. Iliev, Plovdiv A. Ionescu, Bucharest, Romania L. Ivanova, Varna V. Ivanova, Plovdiv I. Mitov, Sofia I. Mokrousov, Saint-Petersburg, Russia P. Moncheva, Sofia M. Murdjeva, Plovdiv R. Peshev, Sofia M. Petrovska, Skopje, FYROM J. C. Piffaretti, Massagno, Switzerland S. Radulovic, Belgrade, Serbia P. Raspor, Ljubljana, Slovenia B. Riteau, Marseille, France J. Rommelaere, Heidelberg, Germany G. Satchanska, Sofia E. Savov, Sofia A. Stoev, Kostinbrod S. Stoitsova, Sofia T. Tcherveniakova, Sofia E. Tramontano, Cagliari, Italy A. Tsakris, Athens, Greece F. Wild, Lyon, France Vol. 31, Issue 2 December 2015 ACTA MICROBIOLOGICA BULGARICA CONTENTS Review Articles Biohydrometallurgy in Bulgaria - Achievements and
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub

    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
  • List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of narcotic substances circulation of which is restricted in Uzbekistan 1. 2C-B(4-bromo-2,5-dimethoxyphenethylamine) 2. 3-methylfentanyl 3. 3-methylthiofentanyl 4. 3-Monoacetylmorphine 5. 4-methylaminorex 6. 6- Monoacetylmorphine 7. Acetorphine 8. Acetyl Dihydrocodeine 9. Acetyl-alfametilfentanil 10. Acetylated opium 11. Acetylcodeine 12. Acetylmethadol 13. Alfametadol 14. Alfatsetilmetadol 15. all fungi that contain Psilocine and Psilocybine 16. Allylprodine 17. Alpha Methylfentanyl 18. Alpha Metiltiofentanil 19. Alphaprodine 20. Anileridin 21. Benzethidine 22. Benzylmorphine 23. Betacetylmethadol 24. Betahydroxyfentanyl 25. Betameprodine 26. Betamethadol 27. Betaprodine 28. Bezitramide 29. Cannabis oil (hashish oil) 30. Cannabis, marihuana 31. Cathine ((+)-norpseudoephedrine) 32. Cathinone (l-alpha-aminopropiofenon) 33. Clonitazene 34. Cocaine 35. Codoxime 36. d- Methadone 37. DB [L-(3,4 - methylenedioxyphenyl) -2 butanamine] 38. Desmethylprodine; MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 39. Desomorphine 40. DET (N,N-diethyltryptamine) 41. Dexamphetamine 42. Diampromide 43. Diethyl phosphate 44. Diethylthiambutene 45. Dihydromorphine 46. Dimenoxadol 47. Dimepheptanol 48. Dimethylthiambutene 49. Dioxaphetyl butyrate 50. Diphenoxine 51. Dipipanone 52. DMA (2,5-dimethoxyamphetamine) 53. DMGP (dimetilgeptilpiran) 54. DMT (dimethyltryptamine) 55. DOB (d, L-2,5-dimethoxy-4-bromo-amphetamine) 56. DOC (d, L-2,5-dimethoxy-4-chloro-amphetamine) 57. DOET (2,5-dimethoxy-4-ethylamphetamine) 58. Drotebanol 59. Ecgonine 60. Ephedrone 61. Ethylmethylthiambutene 62. Eticyclidine 63. Etonitazene 64. Etorphine 65. Etoxeridine 66. Etryptamine 67. Furethidine 68. Hashish (Anasha, cannabis resin) 69. Heroin (Diacetylmorphine) 70. Hydrocodone 71. Hydrocodone phosphate 72. Hydromorphinol 73. Hydromorphone 74. Isomethadone 75. Ketobemidone 76. Khat 77. L- Methadone 78. Levomethorphan 79. Levomoramide 80. Levophenacylmorphan 81. Levorphanol 82. Lysergic acid and its preparations, that include d-Lysergide (LSD, LSD-25) 83.
  • Decision of the Government of the Russian Federation No

    Decision of the Government of the Russian Federation No

    DECISION OF THE GOVERNMENT OF THE RUSSIAN FEDERATION NO. 681 OF JUNE 30, 1998 ON THE APPROVAL OF THE LIST OF NARCOTIC DRUGS, PSYCHOTROPIC SUBSTANCES AND THEIR PRECURSORS THAT SHALL BE SUBJECT TO CONTROL IN THE RUSSIAN FEDERATION In accordance with the Federal Law on Narcotic Drugs and Psychotropic Substances (Sobraniye zakonodatelstva Rossiyskoy Federatsii, 1998, No. 2, item 219) the Government of the Russian Federation resolves: To approve the annexed enumeration of narcotic drugs, psychotropic substances and their precursors that shall be subject to control in the Russian Federation. To establish that the amendment of the said enumeration shall be carried out on presentation of the Ministry of Public Health of the Russian Federation jointly with the Ministry of Internal Affairs of the Russian Federation. Chairman of the Government of the Russian Federation Sergey Kirienko Enumeration of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (Approved by the Decision of the Government of the Russian Federation No. 681 of June 30, 1998) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Prohibited in Accordance with the Legislation of the Russian Federation and the International Treaties of the Russian Federation (List I) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Restricted and in Whose Respect Control Measures Shall Be Established in Accordance with the Legislation of